StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
CLBTBearishLegalnews
Medium materiality6/10

Kaplan Fox investigation into Cellebrite raises concerns after ARR miss and CEO change

Aug 17, 2026, 1:33 PM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting

The combination of ARR miss, guidance cut, and a sudden CEO change, coupled with an external securities investigation, raises material near-term downside risk and uncertain cash-flow implications; historical cases show similar probes can sustain price pressure until clarity emerges.

AI summary

What happened, with direct paths to the underlying reporting

Kaplan Fox & Kilsheimer LLP is probing Cellebrite for potential securities violations after the Q2 ARR miss and an abrupt CEO change. The development follows a 29% stock drop, signaling investor concern and elevated governance risk. Outcomes could affect CLBT's growth trajectory and valuation depending on any resulting litigation or settlements.

  • Q2 ARR $507.8M, below guidance of $510–$513M. Guidance cut ~$15M mid.
  • CEO change: Tom Hogan out, Shiv Ramji in, effective immediately.
  • Cellebrite stock fell 29% to $10.80 on Aug 13, 2026.
  • Kaplan Fox leads securities investigation against Cellebrite.
  • Monitor potential litigation outcomes and their impact on cash flow.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event